# Advances in Lung Cancer Screening and Management: A UK–US Comparative Narrative Review Informed by American Thoracic Society (ATS) 2025 Highlights

**Authors:** Zaw Aung, Chaw Lwin Hsu, Peter Russell

PMC · DOI: 10.7759/cureus.100046 · Cureus · 2025-12-25

## TL;DR

This paper compares lung cancer screening and management practices between the UK and US, highlighting new developments and opportunities for shared learning.

## Contribution

The paper provides a comparative analysis of transatlantic lung cancer care practices informed by the ATS 2025 conference.

## Key findings

- Emerging AI and radiomic tools are being used to support lung cancer diagnosis.
- Updates to TNM staging and quality-of-life assessment approaches were highlighted.
- Differences in diagnostic strategies and healthcare systems between the US and UK were explored.

## Abstract

This narrative review summarises key developments presented at the American Thoracic Society (ATS) 2025 International Conference and examines their relevance to lung cancer care in the United Kingdom, with particular emphasis on transatlantic differences between US and UK practice. Drawing on selected high‑impact plenary sessions, thematic symposia, expert panel discussions, and late‑breaking abstracts covering screening, diagnosis, staging, treatment, and survivorship, the review highlights advances in lung cancer screening eligibility, emerging artificial intelligence (AI) and radiomic tools for diagnostic support, updates to Tumour-Node-Metastasis (TNM) staging, and evolving approaches to quality‑of‑life assessment. UK‑specific perspectives are incorporated, including experience from a single National Health Service (NHS) tertiary centre involving patients diagnosed with lung cancer on clinico‑radiological grounds without tissue confirmation. Differences in diagnostic strategies, healthcare system design, and resource availability between the United States and the United Kingdom are explored to identify opportunities for shared learning and adaptation within NHS lung cancer pathways. This review aims to inform UK clinicians, multidisciplinary teams, and policymakers about international developments and their potential translation into contemporary UK clinical practice.

## Linked entities

- **Diseases:** lung cancer (MONDO:0005138)

## Full-text entities

- **Diseases:** Lung Cancer (MESH:D008175), TNM (MESH:D009362)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12831122/full.md

## References

24 references — full list in the complete paper: https://tomesphere.com/paper/PMC12831122/full.md

---
Source: https://tomesphere.com/paper/PMC12831122